Benzinga’s Top Pre- Market Gainers (CHTT, BUCY, SGEN, INCY, MAIL, ATHX)

Chattem Inc. (NASDAQ: CHTT) has jumped 32% to $92.96 after Sanofi-Aventis SA (ADR) (NYSE: SNY) announced that it has agreed to acquire Chattem Inc. (CHTT) for $1.9 billion in cash, or $93.50 a share. The 52-week trading range for CHTT is $50.10 - $71.95. In the last trading session, CHTT closed at $69.98.

Bucyrus International, Inc. (NASDAQ: BUCY) has moved up 8.20% to $55.01 after Bucyrus International yesterday announced that it has signed an agreement to acquire the mining equipment business of Terex Corporation (NYSE: TEX) for USD1.3 billion in cash. So far in the current year, BUCY gained over 170%. In the last trading session, BUCY closed at $50.84.

Seattle Genetics, Inc. (NASDAQ: SGEN) has surged 3.93% to $9.53 in the pre-market session after Seattle announced that it has entered into an agreement with GlaxoSmithKline (GSK). The 52-week trading range for SGEN is $7.00 - $14.94. In the last trading session, SGEN closed at $9.17.

Incyte Corporation (NASDAQ: INCY) has climbed 6% to $9 after Incyte Genomics and Eli Lilly & Company announced that they have entered into collaboration for the development and commercialization of oral anti inflammatory and autoimmune therapies. In the last trading session, INCY closed at $8.49.

IncrediMail Ltd. (USA) (NASDAQ: MAIL) has increased 4.74% to $9.50 in the pre-market session. The 52 week trading range for MAIL is $2.20 - $10.89. In the previous trading session, MAIL closed at $9.07. So far in 2009, MAIL gained over 285%.

Athersys, Inc. (NASDAQ: ATHX) has moved up 155% to $2.55 in the pre-market session after Athersys today announced that it has agreed to enter into a deal with Pfizer Inc. (NYSE: PFE) to develop and commercialize MultiStem used for the treatment of inflammatory bowel disease. SO far in 2009, ATHX gained over 120%.